Search

The link between excess adiposity and carcinogenesis has been well established for multiple malignancies, and cancer is one of the main contributors to obesity-related mortality. The potential role of different weight-loss interventions on cancer risk modification has been assessed, however, its clinical implications remain to be determined. In this clinical review, we present the data assessing the effect of weight loss interventions on cancer risk.

Breast cancer survivors may experience significant after effects from diagnoses of breast cancer and cancer directed therapies. This review synthesizes the evidence about optimal management of the sequelae of a diagnosis of breast cancer. It describes the side effects of chemotherapy and endocrine therapy and evidence based strategies for management of such effects, with particular attention to effects of therapies with curative intent. It includes strategies to promote health and wellness among breast cancer survivors, along with data to support the use of integrative oncology strategies. In addition, this review examines models of survivorship care and ways in which digital tools may facilitate communication between clinicians and patients. The strategies outlined in this review are paramount to supporting breast cancer survivors’ quality of life.

The effect of high dose ascorbate on urinary oxalate levels in healthy adults was investigated using a modified ion chromatography method. Subjects ingested 1, 5 and 10gm. supplemental ascorbate per day for 5 days, separated by 5 days of no supplementation. Urine ascorbate levels demonstrated variable increases with ascorbate supplementation. Ascorbate added directly to urine in vitro resulted in statistically significant but modest increases in measured oxalate. Addition of 5.68mmol./l. ascorbate increased measured urinary oxalate by 36μmol./l, implying conversion of ascorbate to oxalate during analysis. Measurement of 24-hour urinary oxalate levels with 5 and 10gm. ascorbate per day showed similar, modest increases, which could be entirely accounted for by oxalate production during analytical procedures. Thus, no genuine increase in urinary oxalate was demonstrable despite a greatly increased ascorbate intake.